These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12781708)

  • 21. Chemokine receptor polymorphism and autologous neutralizing antibody response in long-term HIV-1 infection.
    Schønning K; Joost M; Gram GJ; Machuca R; Nielsen C; Nielsen JO; Hansen JE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):195-202. PubMed ID: 9665495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of antibody reactivity to ELDKWA, a glycoprotein 41 neutralization epitope, with disease progression in children perinatally infected with HIV type 1.
    Geffin RB; Scott GB; Melenwick M; Hutto C; Lai S; Boots LJ; McKenna PM; Kessler JA; Conley AJ
    AIDS Res Hum Retroviruses; 1998 May; 14(7):579-90. PubMed ID: 9591712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficient neutralization of primary isolates by the plasma from HIV-1 infected Indian children.
    Prakash SS; Chaudhary AK; Lodha R; Kabra SK; Vajpayee M; Hazarika A; Bagga B; Luthra K
    Viral Immunol; 2011 Oct; 24(5):409-13. PubMed ID: 22004138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
    Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
    J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses.
    Nyambi PN; Nkengasong J; Peeters M; Simon F; Eberle J; Janssens W; Fransen K; Willems B; Vereecken K; Heyndrickx L
    J Infect Dis; 1995 Nov; 172(5):1228-37. PubMed ID: 7594658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of mutations in V3/C3 domain with enhanced sensitivity of HIV-1 clade C primary envelopes to autologous broadly neutralizing plasma antibodies.
    Deshpande S; Patil S; Kumar R; Shrivastava T; Srikrishnan AK; Murugavel KG; Koff WC; Chakrabarti BK; Bhattacharya J
    Retrovirology; 2016 Jun; 13(1):41. PubMed ID: 27307004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to antibody neutralization in HIV-2 infection occurs in late stage disease and is associated with X4 tropism.
    Marcelino JM; Borrego P; Nilsson C; Família C; Barroso H; Maltez F; Doroana M; Antunes F; Quintas A; Taveira N
    AIDS; 2012 Nov; 26(18):2275-84. PubMed ID: 23151495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers.
    Mahalanabis M; Jayaraman P; Miura T; Pereyra F; Chester EM; Richardson B; Walker B; Haigwood NL
    J Virol; 2009 Jan; 83(2):662-72. PubMed ID: 18987151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera.
    Tremblay M; Wainberg MA
    J Infect Dis; 1990 Sep; 162(3):735-7. PubMed ID: 2387997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group.
    D'Souza MP; Livnat D; Bradac JA; Bridges SH
    J Infect Dis; 1997 May; 175(5):1056-62. PubMed ID: 9129066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Presence of neutralizing antibodies to heterologous human immunodeficiency virus type 1 isolates in sera of infected individuals is not predictive of rate of disease progression.
    Warren RQ; Wong MT; Melcher GP; Blatt SP; Zapiola I; Bouzas MB; Muchinik G; Anderson SA; Kennedy RC
    Clin Diagn Lab Immunol; 1995 Jul; 2(4):400-3. PubMed ID: 7583913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralization resistant HIV-1 primary isolates from antiretroviral naïve chronically infected children in India.
    Makhdoomi MA; Singh D; Nair Pananghat A; Lodha R; Kabra SK; Luthra K
    Virology; 2016 Dec; 499():105-113. PubMed ID: 27643887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gp120 V5 Is Targeted by the First Wave of Sequential Neutralizing Antibodies in SHIV
    Jia M; Lu H; Kong XP; Cheng-Mayer C; Wu X
    Viruses; 2018 May; 10(5):. PubMed ID: 29772652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects.
    Cecilia D; Kleeberger C; Muñoz A; Giorgi JV; Zolla-Pazner S
    J Infect Dis; 1999 Jun; 179(6):1365-74. PubMed ID: 10228056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid evolution of the neutralizing antibody response to HIV type 1 infection.
    Richman DD; Wrin T; Little SJ; Petropoulos CJ
    Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4144-9. PubMed ID: 12644702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).
    Bao MJ; Geng WQ; Cui HL; Zhang XL; Xu DB; Nian H; Dai D; Wang YN; Shang H
    Mol Med Rep; 2012 May; 5(5):1311-7. PubMed ID: 22344547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.
    Mascola JR; Sambor A; Beaudry K; Santra S; Welcher B; Louder MK; Vancott TC; Huang Y; Chakrabarti BK; Kong WP; Yang ZY; Xu L; Montefiori DC; Nabel GJ; Letvin NL
    J Virol; 2005 Jan; 79(2):771-9. PubMed ID: 15613305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
    Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
    J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spectrum of HIV-1 neutralizing antibodies in a cohort of homosexual men: results of a 6 year prospective study.
    Robert-Guroff M; Goedert JJ; Naugle CJ; Jennings AM; Blattner WA; Gallo RC
    AIDS Res Hum Retroviruses; 1988 Oct; 4(5):343-50. PubMed ID: 3196490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.